Skip to main content
SpringerLink
Log in

Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit

  • Original Articles
  • Doxorubicin Metabolism, Doxorubicinol Metabolism, Phenytoin, Carditoxicity
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Doxorubicin is metabolized extensively to doxorubicinol by the ubiquitous aldoketoreductase enzymes. The extent of conversion to this alcohol metabolite is important since doxorubicinol may be the major contributor to cardiotoxicity. Aldoketoreductases are inhibited in vitro by phenytoin. The present study was conducted to examine the effect of phenytoin on doxorubicin pharmacokinetics. Doxorubicin single-dose pharmacokinetic studies were performed in 10 New Zealand White rabbits after pretreatment with phenytoin or phenytoin vehicle (control) infusions in crossover fashion with 4–6 weeks between studies. Infusions were commenced 16 h before and during the course of the doxorubicin pharmacokinetic studies. Phenytoin infusion was guided by plasma phenytoin estimation to maintain total plasma concentrations between 20 and 30 μg/ml. Following doxorubicin 5 mg/kg by i.v. bolus, blood samples were obtained at intervals over 32 h. Plasma doxorubicin and doxorubicinol concentrations were measured by HPLC. The mean plasma phenytoin concentrations ranged from 17.4 to 33.9 μg/ml. Phenytoin infusion did not alter doxorubicin pharmacokinetics. The elimination half-life and volume of distribution were almost identical to control. Clearance of doxorubicin during phenytoin administration (60.9±5.8 ml/min per kg, mean±SE) was similar to that during vehicle infusion (67.5±5.4 ml/min per kg). Phenytoin administration was associated with a significant decrease in doxorubicinol elimination half-life from 41.0±4.8 to 25.6±2.8 h. The area under the plasma concentration/time curve (AUC) for doxorubicinol decreased significantly from 666.8±100.4 to 491.5±65.7 n.h.ml-1. These data suggest that phenytoin at clinically relevant concentrations does not alter the conversion of doxorubicin to doxorubicinol in the rabbit. The reduction in the AUC for doxorubicinol caused by phenytoin appears to be due to an increased rate of doxorubicinol elimination. Phenytoin or similar agents may have the effect of modifying doxorubicinol plasma concentrations by induction of doxorubicinol metabolism rather than by inhibition of aldoketoreductase enzymes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ahmed NR, Felsted RL, Bachur NR (1978) Heterogeneity of anthracycline antibiotic carbonyl reductase in mammalian livers. Biochem Pharmacol 27: 2713

    Google Scholar 

  2. Bachur NR, Gee M (1976) Microsomal reductive glycosidase. J Pharmacol Exp Ther 197: 681

    Google Scholar 

  3. Bachur NR, Steele M, Meriweather WP, Hildebrand RC (1976) Cellular pharmacokinetics of several anthracycline antibiotics. J Med Chem 19: 651

    Google Scholar 

  4. Boucek RJ Jr, Olson RD, Brenner DE, Ogunbumi EM, Inui M, Fleischer S (1987) The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ions pumps: a correlative study of cardiac muscle with isolated membrane fractions. J Biol Chem 262: 15851

    Google Scholar 

  5. Bristow MR, Billingham ME, Mason JW, Daniels JR (1978) Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 62: 873

    Google Scholar 

  6. Bristow MR, Minobe WA, Billingham ME, Marmor JB, Johnson CA, Ishimoto BM, Sageman WS, Daniels JR (1981) Anthracycline-associated cardiac and renal damage in rabbits. Evidence of mediation by vasoactive substances. Lab Invest 45: 156

    Google Scholar 

  7. Davies KJA, Doroshow JH (1986) Redox cycling of anthracyclines by cardiac mitochondria: I. Anthracycline radical formation by NADH dehydrogenase. J Biol Chem 261: 3060

    Google Scholar 

  8. Del Tacca M, Danesi R, Ducci M, Bernardini C, Romainine A (1985) Might adriamycinol contribute to adriamycin-induced toxicity? Pharmacol Res Commun 17: 1073

    Google Scholar 

  9. Doroshow JH, Davies KJA (1986) Redox cycling of anthracyclines by cardiac mitochondria: II. Formation of superoxide anion, hydrogen peroxide and hydroxyl radical. J Biol Chem 261: 3068

    Google Scholar 

  10. Doroshow JH, Locker GY, Myers CE (1980) Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest 65: 128

    Google Scholar 

  11. Felsted RL, Richter DR, Bachur NR (1977) Rat liver aldehyde reductase. Biochem Pharmacol 26: 1117

    Google Scholar 

  12. Gervasi PG, Agrillo MR, Citti L, Danes R, Del Tacca M (1986) Superoxide anion production by adriamycinol from cardiac sarcosomes and by mitrochondrial NADH dehydrogenase. Anticancer Res 6: 1231

    Google Scholar 

  13. Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Dekker. New York

    Google Scholar 

  14. Loveless H, Arena E, Felsted RL, Bachur NR (1978) Comparative mammalian metabolism of Adriamycin and daunorubicin. Cancer Res 38: 593

    Google Scholar 

  15. Moore L, Landon EJ, Cooney DA (1977) Inhibition of the cardiac mitochondrial calcium pump by Adriamycin in vivo. Biochem Med 18: 131

    Google Scholar 

  16. Mushlin PS, Boucek RJ, Brenner DE, Cusack BJ, Fleischer S, Olson RD (1986) Doxorubicinol: the culprit in doxorubicin cardiotoxicity? (Abstract) Fed Proc 45: 195

    Google Scholar 

  17. Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC (1975) Adriamycin — the role of lipid peroxidation in cardiac toxicity and tumor response. Science 197: 165

    Google Scholar 

  18. Olson RD, Boerth RC, Gerber JG, Nies AS (1981) Mechanics of Adriamycin cardiotoxicity: evidence for oxidative stress. Life Sci 29: 1393

    Google Scholar 

  19. Olson RD, Brenner DE, Mushlin PS, Boerth RC, Hande KR, Boucek RJ Jr (1985) Doxorubicinol: a more potent cardiotoxin than doxorubicin. Proc Am Assoc Cancer Res 26: 227

    Google Scholar 

  20. Peters JH, Gordon GR, Kashiwase D, Acton EM (1981) Tissue distribution of doxorubicin and doxorubicinol in rats receiving multiple doses of doxorubicin. Cancer Chemother Pharmacol 7: 65

    Google Scholar 

  21. Reich SD, Bachur NR (1976) Alterations in Adriamycin efficacy by phenobarbital. Cancer Res 36: 3803

    Google Scholar 

  22. Rinehart JJ, Lewis RP, Balcerzak SP (1974) Adriamycin cardiotoxicity in man. Ann Intern Med 91: 475

    Google Scholar 

  23. Rossini L, Monti E, Cova D, Piccini F (1986) Determination of doxorubicin and doxorubicin-3-ol in rat heart. Arch Toxicol [Suppl 9]: 474

  24. Saman S, Jacobs P, Opie LH (1984) Mechanism of acute anthracycline cardiotoxicity in isolated rat hearts: carminomycin versus daunomycin. Cancer Res 44: 1316

    Google Scholar 

  25. Singal PK, Panagia V (1984) Direct effects of Adriamycin on the rat heart sarcolemma. Res Commun Chem Pathol Pharmacol 43: 67

    Google Scholar 

  26. Singal PK, Pierce GN (1986) Adriamycin stimulates low affinity Ca binding and lipid peroxidation and depresses myocardial function. Am J Physiol 250: H419

  27. Smolen A, Anderson AD (1976) Partial purification and characterization of a reduced nicotinamide adenine dinucleotide phosphate-linked aldehyde reductase from heart. Biochem Pharmacol 25: 317

    Google Scholar 

  28. Unverferth DV, Magorlen RD, Uverferth BP, Talley RL, Balcerzak SP, Baba N (1981) Human myocardial morphologic and functional changes in the first 24 hours after doxorubicin administration. Cancer Treat Rep 65: 1093

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Pharmacology and Gerontology Research Unit Veterans Administration Medical Center Boise, Idaho, USA

    Barry J. Cusack, Vicki L. Loseke, Robert E. Vestal & Richard D. Olson

  2. Department of Medicine University of Washington Seattle, Washington, USA

    Dwaine A. Tesnohlidek

  3. Roswell Park Memorial Institute Buffalo, NY, USA

    Dean E. Brenner

Authors
  1. Barry J. Cusack
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dwaine A. Tesnohlidek
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vicki L. Loseke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robert E. Vestal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dean E. Brenner
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Richard D. Olson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cusack, B.J., Tesnohlidek, D.A., Loseke, V.L. et al. Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit. Cancer Chemother. Pharmacol. 22, 294–298 (1988). https://doi.org/10.1007/BF00254234

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00254234

Keywords

Search

Navigation